In the rapidly evolving landscape of oncology, the management of prostate cancer—specifically cases marked by high-risk biochemical recurrence (BCR)—has undergone a transformative shift. The phase III EMBARK trial (NCT02319837), a global, multi-center study, has provided what experts describe as "unprecedented" clinical evidence for the efficacy of enzalutamide, both as a monotherapy and in combination with androgen deprivation therapy (ADT).
In a recent expert discussion, principal investigators Dr. Stephen J. Freedland of Cedars-Sinai Medical Center and Dr. Neal Shore of the START Cancer Research Center provided a comprehensive breakdown of the EMBARK findings. Their analysis addresses not only the raw clinical data but also the practical, "real-world" implications for clinicians navigating the complexities of prostate cancer treatment today.
Main Facts: The EMBARK Breakthrough
The EMBARK trial was designed to address a critical gap in prostate cancer care: patients who exhibit signs of recurrence following primary treatment—such as radical prostatectomy or radiation therapy—but who have not yet developed visible, conventional-imaging-confirmed metastatic disease.
The trial’s primary endpoint, metastasis-free survival (MFS), demonstrated that enzalutamide plus leuprolide (a standard LHRH agonist) and enzalutamide monotherapy significantly outperformed leuprolide alone. Most notably, the study revealed a significant overall survival (OS) advantage for the combination of enzalutamide and ADT compared to ADT alone. Crucially, these benefits were achieved without the introduction of new safety signals, and patient-reported outcomes confirmed that health-related quality of life was effectively maintained throughout the treatment cycles.
Chronology: A Decade of Clinical Rigor
The success of EMBARK is the culmination of over a decade of intensive research, patient enrollment, and data analysis.
- Trial Initiation and Design: The study enrolled patients with high-risk BCR, defined by a PSA doubling time of nine months or less. This specific cohort was selected due to the high mortality risk associated with rapid PSA progression.
- The Regulatory Milestone: Following the positive MFS data, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) granted regulatory approval for enzalutamide in this setting.
- Plenary Recognition: The findings were presented at major international forums, including the American Urological Association (AUA) annual meeting and the European Society of Medical Oncology (ESMO) congresses.
- Peer-Reviewed Validation: The trial’s findings were published in two landmark papers in the New England Journal of Medicine, cementing the results as a new pillar in oncology guidelines.
- The 2025 Perspective: Two years post-approval, the investigators are now focusing on the long-term, real-world application of these data, moving beyond the initial trial labels to address clinical nuances such as treatment holidays and the integration of advanced imaging.
Supporting Data: Why Early Intervention Matters
The data from EMBARK are compelling. The combination arm, which utilized ADT and enzalutamide, resulted in a hazard ratio of 0.597 for overall survival, a statistic that reflects a 40% reduction in the risk of death.
"If we wait for patients to develop macrometastatic or imaging-positive disease," Dr. Shore noted during the discussion, "it would not be to the benefit of the patients."
The trial utilized a unique "treatment holiday" protocol. Patients received 37 weeks of treatment. If their PSA levels dropped below 0.2 ng/mL, they were taken off the medication until their PSA levels rose again, at which point they reinitiated the protocol. This cycle allowed patients significant periods of time off therapy, which, combined with the overall survival advantage, demonstrates that the treatment is both highly effective and manageable.
Dr. Freedland underscored the urgency of the situation by comparing it to treating an infection: "If a patient has a UTI, you don’t wait until they are in the ICU with sepsis to provide antibiotics. We have a treatment that reduces the risk of death by 40%. It is hard to argue for a ‘wait and see’ approach when the data is this clear."
Clinical Considerations: Managing the "Real World"
As the EMBARK results move from clinical trials to the physician’s office, several practical questions have emerged.
The Role of PSMA-PET Imaging
Perhaps the most frequently asked question involves patients who appear "conventional imaging-negative" (CIN) but test positive via PSMA-PET scans. Dr. Freedland suggested that while the EMBARK trial did not use PSMA-PET, the reality of current practice is that these patients are often discovered to have occult metastatic disease. "I want to be aggressive," Dr. Freedland stated. "I am going to radiate what I see and initiate systemic therapy. I want to combine the two to get the maximum benefit."
Monotherapy vs. Combination Therapy
Choosing between enzalutamide monotherapy and the combination of enzalutamide and ADT is now a hallmark of shared decision-making. Combination therapy remains the gold standard for maximizing survival. However, monotherapy offers distinct advantages for patients who wish to preserve sexual function or avoid the systemic side effects of traditional ADT.
Managing Side Effects
The discussion also touched on the management of common side effects, such as fatigue and breast-related symptoms. For the latter, the investigators noted that while breast tenderness is a known side effect of unopposed estrogen effects in monotherapy, clinicians have found success using low-dose tamoxifen (a SERM) to mitigate these issues—a strategy that has been discussed in European Urology Focus.
Implications for Future Practice
The legacy of the EMBARK trial extends far beyond its initial regulatory approval. It has fundamentally altered the therapeutic philosophy for high-risk BCR. The trial proved that systemic therapy is not just a palliative measure for those with visible metastases, but a life-prolonging intervention for those at high risk of progression.
Looking ahead, the focus of the oncology community is shifting toward:
- Refining Treatment Holidays: Can patients undergo multiple rounds of treatment suspension? While EMBARK only studied one cycle, clinical experience suggests that individualization is key.
- Multidisciplinary Integration: As the field moves toward more personalized medicine, the role of the "cardio-oncologist" and the "neuro-oncologist" becomes increasingly relevant. While not every patient requires a cardiologist before initiating therapy, the holistic management of bone health, cardiovascular risk, and nutrition is becoming the new standard.
- Standardization of Biomarkers: As PSMA-PET becomes more ubiquitous, there is an urgent need for standardized interpretation of imaging to ensure that patients are accurately staged and treated.
Conclusion
The EMBARK trial has provided a definitive answer to the question of whether early, aggressive intervention is beneficial in high-risk biochemically recurrent prostate cancer. By offering both a clear survival benefit and a flexible approach to treatment cycles, enzalutamide has become a foundational tool in the oncologist’s arsenal. As Dr. Freedland and Dr. Shore concluded, the "art of medicine" now lies in applying these rigorous, evidence-based findings to the individual needs of each patient, ensuring that the promise of the EMBARK trial is fully realized in daily clinical practice.
Disclosures and Acknowledgments:
This article is based on a podcast discussion funded by Pfizer Inc. and Astellas Pharma Inc. Dr. Stephen J. Freedland and Dr. Neal D. Shore have disclosed various financial relationships with pharmaceutical entities, including consulting and advisory roles. Editorial support was provided by the Prime Group of Companies.
About the Author
